What’s New with PD-L1 as a Companion Diagnostic?

Recorded On: 03/24/2021

  • Register
    • Non-member - $30
    • Core Member - $25
    • Student Member - $25
    • Enhanced Member - Free!

Predictive biomarker testing to inform treatment decision-making has radically influenced the practice of both pathology and oncology today. As the treatment scenario evolves, choosing the appropriate biomarker to select the right patients become vital. In this talk we will review the most up-to-date FDA approvals for checkpoint inhibitors and PD-L1 companion diagnostic assays. We will then compare the different PD-L1 scoring systems (TPS, CPS, IC, TC) and point out the role of clinical validation of PD-L1 assays. Finally, we will look at the future of cancer targeted therapies and emerging biomarkers.

CEUs: This histology course is worth 1 continuing education credit. Course is available for 365 days from date of purchase.   

Allie Cummings

Allie Cummings is a Technical Support Representative for Dako/Agilent.  She received her Bachelors in Science from Texas A&M University and then went on to become a certified Histotechnologist in 2011.  She began her career in Histology as a lab aide but after becoming a registered HT she moved to Dallas Children’s Hospital.  At Dallas Children’s she was tasked with the challenge of evaluating and brining in a new IHC platform. She has been in her current role with Dako/Agilent for nearly 6 years.


What’s New with PD-L1 as a Companion Diagnostic?
Open to view video.
Open to view video. This webinar will provide an overview of what is new with PD-L1; Discuss what makes PD-L1 so special; what is means to bring PD-L1 into the lab; and discuss breifly the future of immuno-oncology
On Demand Webinar Survey
2 Questions
2 Questions Please complete the survey to receive your CEU certificate.
1.00 CEUs credit  |  Certificate available
1.00 CEUs credit  |  Certificate available